AstraZeneca to Acquire Icosavax, Including Potential First-in-Class RSV and hMPV Combination Vaccine with Positive Phase II Data

AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. The proposed acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with Icosavax’s lead investigational vaccine candidate, IVX-A12. Under the terms of the agreement, the upfront and maximum potential contingent value payments represent, if achieved, a transaction value of approximately $1.1bn.

Read the full article: AstraZeneca to Acquire Icosavax, Including Potential First-in-Class RSV and hMPV Combination Vaccine with Positive Phase II Data //

Source: https://www.businesswire.com/news/home/20231212478740/en/AstraZeneca-to-Acquire-Icosavax-Including-Potential-First-in-class-RSV-and-hMPV-Combination-Vaccine-With-Positive-Phase-II-Data

Leave a Comment

Your email address will not be published.

Scroll to Top